Chronic hepatitis B is a common infectious and frequent disease in China, and its prevention, treatment and epidemiological status have always been of concern to the public and the industry. With the development and popularization of science, people have a good understanding of the disease, but due to the different cultural levels and social backgrounds, there are still many patients and relatives who have some vague understanding of the disease, and thus add a lot of undue worries and treatment trouble. The following answers to some common questions. 1.Will I be infected if I have contact with hepatitis B patients? Answer: Wrong. Hepatitis B is mainly transmitted by blood and sexual contact, for example, syringes, surgical instruments, razors, toothbrushes, etc. contaminated by the blood of hepatitis B patients and then given to the healthy person to use will be easily infected. Another important mode of transmission is mother-to-child transmission (MTCT), which means that mothers with hepatitis B transmit the virus to the next generation during pregnancy, labor and delivery, and while breastfeeding. However, general contact such as shared meals, conversations, handshakes, and courtesy hugs and kisses are not contagious. Many relatives often ask if they need to share meals when they have a hepatitis B patient at home. Our answer is that meal sharing is scientific and should be advocated, only that the dining habit of our family is to sit at the same table, eat the same bowl of food, be close and joyful, and meal sharing will bring great psychological pressure to the family members. Therefore, whether to share meals should be determined according to the psychological acceptability of family members. 2. The higher the level of Hepatitis B virus DNA in blood, the more serious the disease is? Answer: Wrong. The currently recognized pathogenesis of hepatitis B is that hepatitis B virus does not directly damage liver cells, but the body’s immune system recognizes the hepatitis B virus and causes liver damage in the process of clearing the virus. For people with chronic hepatitis B virus infection, the immune system does not recognize and clear the hepatitis B virus right away, but needs to go through a period of immune tolerance before it can play such a role in recognizing and clearing the virus. Therefore, the level of hepatitis B virus DNA does not reflect the severity of the disease, but only the active degree of viral replication and infectiousness, the higher the level of hepatitis B virus DNA, the more active viral replication, the more infectious. If you want to know the severity of the disease, you should check the liver function, generally speaking, the higher the aminotransferase and bilirubin are, the more serious the disease is. 3. The more serious the patient’s condition is, the more nutrition should be strengthened? Answer: Wrong. For mild hepatitis, it is necessary to strengthen nutrition appropriately, but since liver is an important digestive organ of human body, the more serious the disease is, the more serious the liver damage is. Therefore, eating high nutritious food for patients with severe hepatitis will further increase the burden on the liver, which is not conducive to liver cell repair, and sometimes even play the opposite role, inducing hepatic coma. What is advocated for patients with more severe hepatitis is a light diet that ensures general nutritional needs, such as thin rice, pasta, fresh vegetables, fruit juices, etc., and preferably with fewer and more frequent meals. Failing to recognize this, many people like to carry milk, eggs, or royal jelly and other protein-rich tonic to visit hepatitis patients, which is absolutely inappropriate for the sicker patients. Visiting this kind of patients, it is recommended to send some flowers or fruit can be, fruit can be preferred banana, because banana has laxative effect, help to keep the patient’s intestinal tract open. It is quite important for patients with severe hepatitis to keep their intestines open, otherwise they are prone to hepatic coma. 4.Chronic hepatitis B patients should be actively antiviral treatment? Answer: Yes. Although hepatitis B virus itself does not directly destroy the liver, its presence is a pathogenic factor that induces the body’s immune response and leads to hepatocyte damage, so antiviral is the fundamental treatment for chronic hepatitis B. Through antiviral treatment, liver function can be stabilized, the development of cirrhosis can be prevented or delayed, the incidence of hepatocellular carcinoma can be reduced, and the quality of life of patients can be improved. However, due to the lack of awareness of many patients and their relatives, as well as the factors such as long duration and high cost of antiviral treatment, antiviral treatment has not been completely popularized, and many patients have lost the good time for treatment as a result. However, there are indications for antiviral treatment, that is, antiviral treatment can be considered when the liver function is abnormal and the virus is positive. At present, there are two major types of anti-hepatitis B virus drugs, one is interferon and the other is nucleoside drugs, which have their own advantages and disadvantages. Patients who are willing to take antiviral treatment can make appropriate choices according to their own conditions and the advice of liver disease specialists. 5. Can nucleoside analogs be stopped at any time? Answer: No. Nucleoside analogs are commonly used antiviral drugs for chronic hepatitis B, and their antiviral effect is certain. Some patients who see the liver function continues to be normal and the virus turns negative during the medication period think that there is no need for treatment and stop the medication without authorization, which is extremely wrong and unsafe. This is extremely wrong and unsafe. Unauthorized stopping of medication may lead to the consequences of the previous treatment, virus rebound, recurrence of the disease, and in severe cases, fulminant hepatitis. The course of antiviral treatment with nucleoside analogs is relatively long. Generally speaking, e antigen-negative patients should take the drug for at least 2 years, and e antigen-positive patients should wait for the e antigen to turn negative and e antibody to turn positive, and then consolidate the treatment for another 6 months to 12 months before stopping the drug can be considered. After stopping the drug, the patients should be examined once a month for 3 consecutive months, and the examination time can be gradually extended if the condition has been stabilized. For those who do not meet the criteria for stopping the medication but really want to stop, the medication must be stopped under the guidance of a specialist.